Epstein & White Financial LLC lowered its stake in shares of GlaxoSmithKline plc (NYSE:GSK) by 10.6% during the fourth quarter, HoldingsChannel reports. The firm owned 7,242 shares of the pharmaceutical company’s stock after selling 856 shares during the period. Epstein & White Financial LLC’s holdings in GlaxoSmithKline were worth $280,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the business. Norway Savings Bank increased its holdings in shares of GlaxoSmithKline by 14.9% in the 4th quarter. Norway Savings Bank now owns 4,133 shares of the pharmaceutical company’s stock valued at $158,000 after acquiring an additional 535 shares during the period. Boenning & Scattergood Inc. increased its holdings in shares of GlaxoSmithKline by 71.0% in the 4th quarter. Boenning & Scattergood Inc. now owns 55,061 shares of the pharmaceutical company’s stock valued at $2,104,000 after acquiring an additional 22,867 shares during the period. Moody National Bank Trust Division increased its holdings in shares of GlaxoSmithKline by 1.5% in the 4th quarter. Moody National Bank Trust Division now owns 34,108 shares of the pharmaceutical company’s stock valued at $1,303,000 after acquiring an additional 508 shares during the period. Waldron Private Wealth LLC increased its holdings in shares of GlaxoSmithKline by 10.0% in the 3rd quarter. Waldron Private Wealth LLC now owns 5,500 shares of the pharmaceutical company’s stock valued at $220,000 after acquiring an additional 500 shares during the period. Finally, Cullinan Associates Inc. increased its holdings in shares of GlaxoSmithKline by 27.2% in the 4th quarter. Cullinan Associates Inc. now owns 29,500 shares of the pharmaceutical company’s stock valued at $1,127,000 after acquiring an additional 6,300 shares during the period. 10.89% of the stock is currently owned by institutional investors.

A number of equities analysts have recently commented on the stock. Zacks Investment Research cut shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Tuesday, December 4th. Barclays cut shares of GlaxoSmithKline from an “overweight” rating to an “equal weight” rating and set a $36.95 target price on the stock. in a report on Tuesday, December 4th. Cfra reaffirmed a “hold” rating on shares of GlaxoSmithKline in a report on Tuesday, December 4th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of GlaxoSmithKline in a report on Monday, December 3rd. Finally, Exane BNP Paribas cut shares of GlaxoSmithKline from an “outperform” rating to a “neutral” rating in a report on Monday, January 14th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $41.71.

Shares of GSK opened at $41.09 on Monday. The company has a debt-to-equity ratio of 5.52, a quick ratio of 0.51 and a current ratio of 0.75. The firm has a market capitalization of $101.93 billion, a price-to-earnings ratio of 13.00, a PEG ratio of 2.15 and a beta of 0.79. GlaxoSmithKline plc has a 1 year low of $35.57 and a 1 year high of $42.36.

GlaxoSmithKline (NYSE:GSK) last issued its earnings results on Wednesday, February 6th. The pharmaceutical company reported $0.79 EPS for the quarter, topping the consensus estimate of $0.70 by $0.09. The company had revenue of $10.55 billion for the quarter, compared to analyst estimates of $9.85 billion. GlaxoSmithKline had a net margin of 11.45% and a return on equity of 160.39%. As a group, equities research analysts expect that GlaxoSmithKline plc will post 2.94 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, April 11th. Shareholders of record on Friday, February 22nd will be given a dividend of $0.597 per share. This is a positive change from GlaxoSmithKline’s previous quarterly dividend of $0.49. This represents a $2.39 annualized dividend and a dividend yield of 5.81%. The ex-dividend date is Thursday, February 21st. GlaxoSmithKline’s payout ratio is presently 60.76%.

COPYRIGHT VIOLATION WARNING: “GlaxoSmithKline plc (GSK) Shares Sold by Epstein & White Financial LLC” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another domain, it was copied illegally and republished in violation of United States and international copyright laws. The legal version of this story can be viewed at https://www.thecerbatgem.com/2019/02/11/glaxosmithkline-plc-gsk-shares-sold-by-epstein-white-financial-llc.html.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Featured Article: How are institutional investors different from individual investors?

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.